Influenza A viruses have caused major influenza outbreak or pandemic that affected millions of people worldwide. The viruses are divided into subtypes based on two proteins on their surface: hemagglutinin (H) and neuraminidase (N). These subtypes have been responsible for major pandemics throughout the 20 th and 21 st centuries such as the H1N1 pandemic in 1918, H2N2 pandemic in 1957, and H3N2 pandemic in 1968. and H5N1, , H1N1, 5-6 H5N8, and H7N9 8 in recent years. New strains of the viruses continue to emerge and the risk of drug resistance have sparked great interest into finding potential anti-viral compounds. Neuraminidase is a key surface glycoprotein which plays an important role in viral replication and infection. It is a proven target for developing drugs against influenza A viruses . Several drugs recommended for treating influenza virus such as oseltamivir, zanamivir, and peramivir are neu-raminidase inhibitors. However, these drugs suffer from serious limitations such as the emergence of oseltamivir-resistant strains , the poor oral bioavailability of zanamivir 20 . On the other hand, more virulent variants, such as H5N1 and H7N9 has emerged. Therefore, researching novel inhibitors capable of effectively inhibiting neuraminidase continue to be a topic of interest.